✦ LIBER ✦

When less is more: A simple predictive model for repeated prostate biopsy outcomes

✍ Scribed by Vencalek, Ondrej; Facevicova, Kamila; Furst, Tomas; Grepl, Michal

Book ID: 123132109
Publisher: Elsevier
Year: 2013
Tongue: English
Weight: 325 KB
Volume: 37
Category: Article
ISSN: 1877-7821
DOI: 10.1016/j.canep.2013.08.015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

DECLARING A MORATORIUM ON REPEAT BIOPSIE

DECLARING A MORATORIUM ON REPEAT BIOPSIES: A NEW STATISTICAL METHOD FOR PREDICTING WHEN REPEAT PROSTATE BIOPSIES ARE UNNECESSARY

✍ Fought, Angela J; Vonesh, Edward F; Zhao, Lee C; Kim, Dae Y; Catalona, William J 📂 Article 📅 2008 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 169 KB

PROSTATE VOLUME AT INITIAL BIOPSY IS THE

PROSTATE VOLUME AT INITIAL BIOPSY IS THE MOST IMPORTANT PREDICTOR OF REPEAT BIOPSY OUTCOME. VALIDATION OF A NOVEL PREDICTIVE TOOL

✍ Chun, F.K.H.; Briganti, A.; Ahyai, S.; Walz, J.; Scattoni, V.; Salonia, A.; Steu 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 60 KB

979 PSA VELOCITY AND PCA3 SCORE AS RISK

979 PSA VELOCITY AND PCA3 SCORE AS RISK FACTORS FOR PROSTATE CANCER IN A REPEAT BIOPSY SETTING IMPROVES THE PREDICTIVE ACCURACY IN A MULTIVARIATE MODEL

✍ M. Auprich; L. Budäus; F. Luger; M. Pichler; G. Galle; S. Mannweiler; F.K.H. Chu 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 81 KB

Can multiparametric magnetic resonance i

Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology?11Mohamed Abd-Alazeez receives funding from the Egyptian government. Mark Emberton and Hashim U. Ahmed receive funding from USHIFU and Advanced Medical Diagnostics for clinical trials. Mark Emberton is a paid consultant for Steba Biotech, USHIFU and Sanofi-Aventis. Mark Emberton has received research support by GSK for a study evaluating the role of MRI in men with prostate cancer. Mark Emberton and Hashim Ahmed have previously received medical consultancy fees from GE Healthcare/Oncura and Hashim Ahmed previously from Steba Biotech. Mark Emberton is a medical director of Mediwatch PLC. Hashim Uddin Ahmed and Mark Emberton receive funding from the Medical Research Council, the NIHR-HTA, NIHR-i4i, the US NIH/NCI, Pelican Cancer Foundation, Prostate Cancer UK, and St Peter׳s Trust. This work was part funded by research support for Mark Emberton and Alex Kirkham from the UK National Institute of Health Research UCLH/UCL Comprehensive Biomedical Research Centre, London, UK.

✍ Abd-Alazeez, Mohamed; Ahmed, Hashim U.; Arya, Manit; Allen, Clare; Dikaios, Niko 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 415 KB